OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages
Seven brokerages have issued a "Hold" recommendation for OPKO Health, Inc. (NASDAQ:OPK), with an average 12-month price target of $2.2833. Analysts' ratings range from "sell" to "strong buy," reflecting varied opinions on the stock. Institutional investors have significantly adjusted their positions, with notable increases in holdings by major firms.
OPKO Health (OPK) Projected to Post Quarterly Earnings on Thursday
OPKO Health (OPK) is expected to announce its Q4 2025 earnings after market close on Thursday, February 26th, with projected EPS of ($0.07) and revenue of $139.757 million. The company has seen significant insider activity, including CEO Phillip Frost's purchase of 580,000 shares, bringing insider ownership to 49.69%. Analysts currently hold a consensus "Hold" rating for OPK, with a price target of $2.28.
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation
Opko Health Inc. (OPK) is highlighted as a high-return penny stock due to its partnerships and innovation. H.C. Wainwright reiterated a Buy rating with a $3 price target, citing progress in biological collaborations including an expanded partnership with Entera Bio for a long-acting parathyroid hormone analog. This collaboration aims to transform hypoparathyroidism treatment, with positive preclinical results and an IND filing planned for late 2026, where both companies share 50% ownership and development costs.
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation
Opko Health Inc. (OPK) has received a reiterated Buy rating and a $3 price target from H.C. Wainwright, due to progress in its biological partnerships. The company's subsidiary is expanding collaboration with Entera Bio for an oral, long-acting parathyroid hormone analog, with positive results and an IND filing planned for late 2026. This partnership gives both companies 50% ownership and shared development costs, highlighting OPK's diversified approach in diagnostics and pharmaceuticals.
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
OPKO Health, Inc. (NASDAQ: OPK) announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the U.S. financial markets close on Thursday, February 26, 2026. Senior management will host a conference call and webcast at 4:30 p.m. Eastern time to provide a business update, discuss results, and offer financial guidance. Participants can pre-register for the call or access it via dial-in or the company's Investor Relations page.
OPKO Health, Inc. to Announce 2025 Financial Results on February 26, 2026
OPKO Health, Inc. will report its operating and financial results for the three and twelve months ending December 31, 2025, on February 26, 2026, after the U.S. market closes. Senior management will host a conference call and live audio webcast at 4:30 p.m. Eastern Time to provide a business update and discuss the results and financial guidance. Interested parties can pre-register for the call or access it via standard dialing, with replays available afterward.
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
OPKO Health, Inc. (NASDAQ: OPK) announced it will report its Q4 and full-year 2025 financial results after the market closes on February 26, 2026. Senior management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide financial guidance. Interested parties can pre-register for the call or access details through the company's investor relations page.
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development
Opko Health (OPK) has expanded its partnership with Entera Bio Ltd. to co-develop an oral long-acting PTH analog for hypoparathyroidism, aiming to file an IND application in late 2026. Both companies will share 50% ownership and development costs for this program. They also maintain their existing 60/40 ownership structure for the oral OXM program for metabolic and fibrotic disorders.
Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism
Opko Health and Entera Bio have expanded their partnership to develop a first-in-class oral, long-acting parathyroid hormone (PTH) tablet for patients suffering from hypoparathyroidism. This collaboration aims to advance a new treatment option for this condition. The news was reported by Refinitiv.
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board
Entera Bio (NASDAQ: ENTX) has expanded its collaboration with OPKO Health to include the joint development of a daily long-acting PTH tablet for hypoparathyroidism, in addition to their existing GLP-1/glucagon program. Development costs for the new LA-PTH program will be shared equally. Additionally, the company announced the resignation of director Gerald Ostrov and the appointment of Steven D. Rubin as a Class III director, who will also serve as Chairman of the audit committee.
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
OPKO Health and Entera Bio have expanded their partnership to accelerate the development of a first-in-class oral long-acting PTH analog (LA-PTH) for hypoparathyroidism, aiming for an IND application in late 2026. This collaboration, which includes a 50/50 ownership and cost-sharing split for the LA-PTH program, builds on their existing work on an oral oxyntomodulin for metabolic disorders. The companies anticipate providing a more convenient, once-daily tablet treatment, eliminating the need for daily injections currently required for hypoparathyroidism patients.
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK)
The article highlights OPKO Health (OPK) as a deeply undervalued company with significant potential due to its partnerships with Merck, Regeneron, and BARDA for developing COVID-19, influenza, and cancer treatments, along with EBV vaccines. The company's financial health is improving with decreasing debt, and analysts project a favorable P/S ratio by 2030. These factors, alongside upcoming clinical trial readouts and its MSTAR platform, suggest an attractive risk/reward profile for long-term investors.
OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of "Hold" from Analysts
Seven analysts have issued ratings for OPKO Health (NASDAQ:OPK), resulting in a consensus "Hold" rating with an average 12-month target price of $2.28. Despite a recent earnings beat of $0.03 EPS, revenue declined by 12.6% year-over-year. Insiders, including CEO Phillip Frost, have been buying shares, with insiders now owning nearly 50% of the company.
OPKO Health, Inc. (NASDAQ:OPK) insiders have recently purchased stock and their bets paid off last week as company hit US$1.0b market cap
Insiders at OPKO Health, Inc. (NASDAQ:OPK) recently purchased company stock, and these investments proved profitable as the company achieved a US$1.0 billion market capitalization last week. Individual insiders collectively own 42% of the company, with CEO Phillip Frost holding 29% of outstanding shares. This significant insider ownership suggests a strong vested interest in the company's growth, and the stock saw a 7.9% gain, benefiting these recent insider purchases.
Clinical Laboratory Services Market is expected to reach US$ 422.66 Billion by 2033 | Major players - Abbott, OPKO Health, Inc., Quest Diagnostics, Myriad Genetics, Inc.
The Clinical Laboratory Services Market is projected to grow from US$ 288.05 billion in 2024 to US$ 422.66 billion by 2033, exhibiting a CAGR of 4.4%. This growth is driven by increasing chronic diseases, demand for preventive screening, and technological advancements. Key players in this market include Abbott, Quest Diagnostics, and Labcorp, all actively engaging in strategic partnerships and acquisitions to expand their offerings.
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled from January 12-15, 2026, in San Francisco. Management will engage in one-on-one meetings with investors and host a live-streamed fireside chat on January 14th at 1:30 p.m. Pacific time. The biopharmaceutical and diagnostics company aims to leverage this platform to showcase its expertise and technologies.
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. announced its management will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. Management will host one-on-one meetings and a webcast fireside chat on January 14th at 1:30 p.m. Pacific time. The fireside chat will be available for replay on OPKO Health’s website.
OPKO Health, Inc. to Participate in 44th Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. Management will hold one-on-one meetings and a fireside chat on January 14 at 1:30 p.m. Pacific time, which will be webcast live. OPKO Health is a biopharmaceutical and diagnostics company.
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, taking place from January 12-15, 2026, in San Francisco. Management will conduct one-on-one meetings with investors and host a fireside chat on January 14th at 1:30 p.m. Pacific time, which will be webcast live. OPKO is a multinational biopharmaceutical and diagnostics company focused on establishing leading positions in growing markets.
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. Management will host one-on-one meetings and a fireside chat on January 14th at 1:30 p.m. Pacific time, which will be webcast live. OPKO is a multinational biopharmaceutical and diagnostics company.
Opko Health, Inc. (OPK) Investor Outlook: Assessing A Potential 177.99% Upside
Opko Health, Inc. (OPK) presents a high-risk, high-reward investment opportunity with a potential upside of nearly 178%, despite current financial challenges. The diagnostics and pharmaceuticals company faces negative earnings, revenue contraction, and negative free cash flow. However, its diversified portfolio, including flagship products and strategic developments in immune therapies, provides growth prospects, with analysts showing cautious optimism.
OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of "Hold" from Analysts
OPKO Health, Inc. (NASDAQ:OPK) has received an average "Hold" rating from seven research firms, with an average 12-month price target of $2.2833. Insiders, including CEO Phillip Frost, have recently bought approximately 1.84 million shares, increasing their ownership to nearly 49.69%. Despite beating EPS estimates, the company missed revenue targets in its latest quarterly report and continues to show negative net margin and return on equity.
OPKO Health (NASDAQ:OPK) Stock Crosses Below 50 Day Moving Average - Here's Why
OPKO Health (NASDAQ:OPK) stock recently fell below its 50-day moving average, trading as low as $1.25 and settling at $1.26, indicating short-term technical weakness despite significant insider buying from CEO Phillip Frost. Analysts have a "Hold" consensus rating with an average price target of $2.28, reflecting mixed opinions and recent downward revisions. The company reported better-than-expected EPS for its last quarter but saw a year-over-year revenue decline.
OPKO Health (NASDAQ:OPK) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen upgraded OPKO Health (NASDAQ:OPK) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating from analysts with a $2.28 price target. Insiders, notably CEO Phillip Frost, have significantly increased their stake, owning nearly 50% of the company after recent large purchases. Despite beating EPS estimates, OPKO Health missed revenue forecasts, with analysts predicting a negative EPS for the current fiscal year.
OPKO Health (NASDAQ:OPK) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded OPKO Health (NASDAQ:OPK) from "hold" to "sell," while MarketBeat's consensus rating remains "Hold" with an average price target of $2.28. Despite the company being unprofitable, CEO Phillip Frost recently purchased 580,000 shares, bringing insider ownership to nearly 50%. The company reported Q3 EPS of $0.03, beating estimates, but revenue saw a 12.6% year-over-year decline.
Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals
Opko Health Inc.'s ModeX Therapeutics has entered into a license and collaboration agreement with Regeneron Pharmaceuticals. This agreement grants Regeneron an exclusive global license to develop and commercialize ModeX's preclinical, multispecific antibody programs for oncology and infectious diseases. ModeX will receive an upfront payment and is eligible for substantial milestone payments and royalties on future sales.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now
OPKO Health, Inc. (OPK) is positioned for growth, primarily driven by its leading renal product, RAYALDEE, and several strategic partnerships. Despite facing stiff competition and a reliance on RAYALDEE, the company has shown strong earnings performance, surpassing estimates in two of the last four quarters. Several clinical trials and collaborations further underpin its potential for future growth.
OPKO Health, Inc. (NASDAQ:OPK) Given Average Rating of "Hold" by Brokerages
OPKO Health, Inc. (NASDAQ:OPK) has received a consensus "Hold" rating from seven brokerages, with an average one-year price target of $2.28. Insider activity shows CEO Phillip Frost purchased 580,000 shares, bringing total insider ownership to 49.69%. Despite beating earnings per share estimates, the company's revenue missed consensus, and it currently holds a negative net margin.
Geode Capital Management LLC Increases Stake in OPKO Health, Inc. $OPK
Geode Capital Management LLC significantly increased its holdings in OPKO Health, Inc. by 23.7% in Q2, bringing its total to over 10.4 million shares worth approximately $13.8 million. Concurrently, OPKO Health's CEO, Phillip Md Et Al Frost, also boosted his direct holdings by purchasing 580,000 shares. Despite the increased institutional and insider interest, analysts currently have a "Hold" rating on OPKO Health with an average price target of $2.28, noting the company remains unprofitable despite beating modest EPS expectations.
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
OPKO Health, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York City. Management will engage in one-on-one meetings with investors and a fireside discussion on December 3rd. Investors interested in scheduling a meeting should contact their Piper Sandler representative.
OPKO Health (OPK): Evaluating Valuation After Insider Buying and Sales Concerns on Ngenla
OPKO Health (OPK) is seeing investor focus after its CEO bought over $730,000 in stock, despite Jefferies downgrading the company due to cautious sales expectations for Ngenla. While the stock is largely perceived as undervalued by a significant margin, trading at $1.31 against an estimated fair value of $3.62, its current price-to-sales ratio is higher than industry averages, suggesting a premium not justified if growth doesn't accelerate. The company's future hinges on its ability to leverage the BioReference asset sale for profitability in its core testing business and achieve margin expansion.
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
OPKO Health, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York City. Management will engage in one-on-one meetings with investors and a fireside discussion on December 3rd at 12:00 p.m. EST. Investors interested in scheduling a meeting are advised to contact their Piper Sandler representative.
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
OPKO Health, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. Management will engage in one-on-one investor meetings and a fireside discussion on December 3rd. Investors are encouraged to contact their Piper Sandler representative to schedule meetings with OPKO management.
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. reported its third-quarter 2025 financial results and business highlights, including a new research collaboration with Regeneron Pharmaceuticals and the sale of BioReference oncology assets to Labcorp for $225 million. The company achieved a net income of $21.6 million for the quarter, compared to $24.9 million in the prior year, with various advancements in its pharmaceutical pipeline and diagnostic services. OPKO also detailed its cash position and share repurchase program.
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
OPKO Health reported its Q3 2025 financial results, including a net income of $21.6 million, significantly impacted by the sale of BioReference oncology assets to Labcorp for $225 million. The company also announced key business highlights such as a research collaboration with Regeneron for multispecific antibodies, advancements in several clinical trials for oncology candidates and metabolic disorders, and FDA approval for the 4Kscore® Test without a digital rectal examination.
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
OPKO Health (OPK) reported a wider-than-expected loss per share and lower-than-anticipated revenues for Q2 2025, leading to a 3.1% dip in after-hours trading. While overall revenues were down 13.9% year-over-year due to decreased services, the company saw some positive movement with increased product revenues, intellectual property transfers, and an expanded gross margin. OPKO Health has adjusted its full-year 2025 revenue guidance downward, reflecting a cautious outlook despite advancements in its product pipeline.
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
OPKO Health, Inc. (NASDAQ: OPK) announced it will report its second quarter 2025 financial results on July 31, 2025, after the close of U.S. financial markets. The company will host a conference call and live audio webcast at 4:30 p.m. Eastern time on the same day to provide a business update and discuss results and financial guidance. Participants are encouraged to pre-register for the call.
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
OPKO Health, Inc. announced its participation in the 3rd Annual Piper Sandler Virtual Obesity Symposium on June 26, 2025. Management will engage in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors interested in attending can register by contacting their Piper Sandler representative.
Opko Health, Inc. (OPK) Stock Analysis: A Look At The 200% Potential Upside
Opko Health, Inc. (OPK) is a diversified healthcare company with a stated market capitalization of $1.05 billion and a potential upside of 200.13%, according to analysts. Despite current challenges including negative earnings and revenue decline, the company's strong pipeline in diagnostics and pharmaceuticals, along with positive analyst sentiment, suggests significant growth potential. Investors are advised to conduct thorough due diligence due to the inherent risks in biotech investments.
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
ModeX Therapeutics Inc., an OPKO Health company, has announced the formation of a Scientific Advisory Board composed of leading experts in immunology and oncology. This board will provide guidance on the development of ModeX’s pipeline of multispecific antibodies and vaccines, which utilize its proprietary MSTAR platform technology. The founding members include distinguished researchers Drs. John Heymach, Ronald Levy, Myron Cohen, and Rafi Ahmed, aiming to advance next-generation immune therapies for complex diseases.
OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
OPKO Health (NASDAQ:OPK) has a notable amount of debt, with US$437.2m in debt and US$426.6m in cash as of December 2024, resulting in net debt of US$10.6m. The company's liabilities exceed its near-term assets by US$279.9m, an amount that, while potentially manageable given its US$940.2m market capitalization, is concerning when coupled with its US$274m EBIT loss and 17% revenue drop over the past year. Analysts therefore suggest close monitoring of OPKO Health's financial health due to these risks.
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. announced its first-quarter 2025 business highlights and financial results, including the sale of BioReference Health's oncology testing assets to Labcorp for up to $225 million and a collaboration with Entera Bio for an oral GLP-1/glucagon tablet. The company reported consolidated total revenues of $149.9 million, an operating loss of $67.2 million, and a net loss of $67.6 million, or $0.10 per share. OPKO also increased its common stock repurchase program authorization by an additional $100 million, bringing the total to $200 million.
OPKO Health unit to pay $10 mln to resolve U.S. probe into lab referrals
OPKO Health Inc. has agreed to pay $10 million to settle allegations that its lab services unit, BioReference Health LLC, paid above-market rates for office space to doctors in exchange for referrals. The U.S. Department of Justice stated the settlement resolves claims that originated in a whistleblower lawsuit alleging violations of the Physician Self‑Referral Law and the Anti-Kickback Statute. BioReference admitted to certain conduct, acknowledging it included a disproportionate share of common spaces when calculating rent for centers in physicians' offices.
What You Need To Know About OPKO Health, Inc.'s (NASDAQ:OPK) Investor Composition
This article examines the ownership structure of OPKO Health, Inc. (NASDAQ:OPK), highlighting the significant influence of institutional investors and the CEO, Phillip Frost. It details the percentages held by various groups including institutions, insiders, the general public, and private companies, and discusses the implications of these holdings for the company's governance and future performance.
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Sema4 announced the acquisition of GeneDx, a leader in genomic testing, from OPKO Health, Inc. This strategic move is expected to create one of the largest genomic clinical testing providers in the U.S., with projected pro forma 2022 revenue of $350 million. The acquisition will be supported by a $200 million private placement, including investment from Pfizer, and will integrate GeneDx's extensive genomic data with Sema4's AI-driven health intelligence platform to enhance precision medicine solutions.
BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business
BioReference Laboratories, an OPKO Health company, announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche. This acquisition expands BioReference's non-invasive prenatal screening (NIPS) offerings, complementing its existing ClariTest™ Core, which utilizes similar technology to Ariosa's Harmony Prenatal Test. The move reinforces BioReference's commitment to women's health and high-quality, accessible prenatal screening.
Mon: Budget agreement boosts TASE
The Tel Aviv Stock Exchange (TASE) saw a boost following the cabinet's approval of Israel's first budget in three years. Banks, including Bank Hapoalim and Bank Leumi, led the gains, while Opko Health and Azrieli Group were among the few decliners.
Human Growth Hormone Market Is Seeing Phenomenal Growth
The Human Growth Hormone (HGH) market is experiencing significant growth, driven by new mergers, acquisitions, and a robust drug pipeline. Key players like Pfizer Inc. and Novo Nordisk are developing innovative treatments, with somapacitan and MOD-4023 showing promise in clinical trials. Despite strong growth, strict regulations on HGH use by athletes and sports professionals are expected to temper market expansion.
OPKO Health Appoints Katherine Stueland as CEO of GeneDx
OPKO Health announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., its global genomics subsidiary. Stueland brings extensive experience from Invitae Corporation, where she served as Chief Commercial Officer, and is expected to lead GeneDx into a new era of genomics, focusing on patient-centric strategies and broader access to diagnostic technologies.
OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland
OPKO Health, Inc. announced the sale of its sterile fill and finish manufacturing facility in Waterford, Ireland, belonging to its subsidiary EirGen Pharma, Ltd., to Horizon Therapeutics plc for $65 million in cash. This sale allows OPKO to focus EirGen's business on oral solid dose products, strengthen its balance sheet, and improve efficiency. The transaction is expected to close in approximately one month, subject to governmental consent and customary closing conditions.
